Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
    • Podcast
  • Press Release
  • Media Coverage
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Clinical Trial Improves Outcomes for Older Patients With Hodgkin Lymphoma
Clinical Breakthroughs

Clinical Trial Improves Outcomes for Older Patients With Hodgkin Lymphoma

By Anna WilliamsSep 27, 2018
Share
Facebook Twitter Email
Leo I. Gordon, MD, the Abby and John Friend Professor of Cancer Research and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, was a senior author of the study published in the Journal of Clinical Oncology.

A novel chemotherapy regimen improved overall survival in older patients with Hodgkin lymphoma, who in the past have generally shown worse outcomes than younger patients, according to the results of a Northwestern Medicine clinical trial.

“Older patients now can be treated with expectations for outcomes similar to younger patients,” said Leo I. Gordon, MD, the Abby and John Friend Professor of Cancer Research, and a senior author of the study published in the Journal of Clinical Oncology.

Gordon is also a professor of Medicine in the Division of Hematology and Oncology and a member of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University.

Hodgkin lymphoma is a cancer that originates in a type of white blood cell called lymphocytes. In general, outcomes for patients with Hodgkin lymphoma who are 60 years or older tend to be poor, when compared with younger patients. The causes are not well understood, although factors like co-morbidities, biological differences and increased treatment-related toxicities may all play a role.

In order to improve outcomes in such patients, a team of investigators conducted a clinical trial evaluating a novel drug regimen. The multi-site phase II trial included 48 patients with a median age of 69 years who had been newly diagnosed with Hodgkin lymphoma. In the trial, the participants received brentuximab vedotin — an immunoconjugate drug — before and after a standard chemotherapy regimen of doxorubicin, vinblastine and dacarbazine.

The regimen resulted in the best-reported outcomes to date in this patient population, according to the authors, with two-year progression-free survival and overall survival rates of 84 percent and 95 percent, respectively.

The investigators also found that the regimen was well-tolerated by patients.

“The next steps for research are to begin to shorten the regimen and combine it with checkpoint inhibitors, which are novel antibodies that enhance the immune response,” Gordon explained.

In the course of the study, the investigators also examined a number of baseline geriatric assessment measures — such as co-morbidities and functional status — and found them to be strongly associated with patient survival. The findings provide important prognostic guidelines.

The study was led by Northwestern, in collaboration with Memorial Sloan Kettering Cancer Center, Stanford University, MD Anderson Cancer Center, the University of Chicago, the University of Nebraska and Tufts University. It was supported by Seattle Genetics, which manufactures brentuximab vedotin.

Cancer Research
Share. Facebook Twitter Email

Related Posts

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Comments are closed.

Latest News

Physician Assistant Students Embrace ‘Shades of Purple’

Jul 1, 2022

Dissolving Implantable Device Relieves Pain Without Drugs

Jun 30, 2022

Fathers’ Presence During Childhood Predicts Adult Testosterone Levels

Jun 29, 2022

Epigenetic Biomarkers Predict CVD Risk

Jun 28, 2022

Student Spearheads Ukraine Aid Efforts

Jun 27, 2022
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
20220617_NM_0434
20220617_NM_0858
20220617_NM_0643
20220617_NM_0835
20220617_NM_0544
20220617_NM_0450
20220617_NM_0790
20220617_NM_0811
20220617_NM_0851
20220617_NM_0696
20220617_NM_0779
20220617_NM_0838

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2022 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.